SCHEMBL11809392

SCHEMBL11809392

C/C=C(\C#N)C(C)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11965638 1.00
SCHEMBL11809406 1.00
SCHEMBL11856272 0.79 TDP1 (0.35)
SCHEMBL11856278 0.79 TDP1 (0.35)
SCHEMBL19019192 0.79 TDP1 (0.35)
SCHEMBL1579883 0.76 CYP2C9 (0.55)
SCHEMBL18959027 0.76 MEN1 (0.34)
SCHEMBL1579884 0.76 CYP2C9 (0.55)
SCHEMBL16646930 0.76 EGFR (0.32)
SCHEMBL1959929 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023154282-A1 COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS THERAS, INC. (US) 2023-08-17 WO disclosed
US-20230143040-A1 PROCESS FOR PREPARING 5-(FLUORO-4-IMINO-3-METHYL)-1-TOSYL-3,4 DIHYDROPYRIMIDINE-(1H)-ONE AND DERIVATIVES OF THE COMPOUND ADAMA MAKHTESHIM LTD. (IL) 2023-05-11 US disclosed
WO-2023069959-A1 COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-04-27 WO disclosed
US-9810690-B2 Method for screening inhibitors of Ras ARAXES PHARMA LLC (US) 2017-11-07 US disclosed
US-20170247391-A1 THIENOPYRIMIDINE AND THIENOPYRIDINE COMPOUNDS AND METHODS OF USE THEREOF WELLSPRING BIOSCIENCES LLC 2017-08-31 US disclosed
US-20170131278-A1 METHOD FOR SCREENING INHIBITORS OF RAS ARAXES PHARMA LLC 2017-05-11 US disclosed
US-9359327-B2 Process for the preparation of substituted pyrimidine derivatives JANSSEN PHARMACEUTICA NV (BE) 2016-06-07 US disclosed
US-9079882-B2 Process for the preparation of substituted pyrimidine derivatives JANSSEN PHARMACEUTICA NV (BE) 2015-07-14 US disclosed
US-9079883-B2 Process for the preparation of substituted pyrimidine derivatives JANSSEN PHARMACEUTICA NV (BE) 2015-07-14 US disclosed
US-9079884-B2 Process for the preparation of substituted pyrimidine derivatives JANSSEN PHARMACEUTICA NV (BE) 2015-07-14 US disclosed
WO-2014093230-A2 COMPOSITIONS AND METHODS FOR THE PRODUCTION OF PYRIMIDINE AND PYRIDINE COMPOUNDS WITH BTK INHIBITORY ACTIVITY MERCK PATENT GMBH (DE) 2014-06-19 WO disclosed
US-20140121374-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (US) 2014-05-01 US disclosed
US-20140073795-A1 Process for the preparation of substituted pyrimidine derivatives JANSSEN PHARMACEUTICA NV (US) 2014-03-13 US disclosed
US-20140066624-A1 Process for the preparation of substituted pyrimidine derivatives JANSSEN PHARMACEUTICA NV (US) 2014-03-06 US disclosed
US-20130274212-A1 Sesterterpene Compounds and Use Thereof SNU R&DB FOUNDATION (KR) 2013-10-17 US disclosed
US-20130225816-A1 Process for the preparation of substituted pyrimidine derivatives JANSSEN PHARMACEUTICA NV (US) 2013-08-29 US disclosed
US-20130053561-A1 Process for the preparation of substituted pyrimidine derivatives JANSSEN PHARMACEUTICA NV (US) 2013-02-28 US disclosed
US-8309720-B2 Process for the preparation of substituted pyrimidine derivatives JANSSEN PHARMACEUTICA NV (BE) 2012-11-13 US disclosed
US-20100004450-A1 Process for the preparation of substituted pyrimidine derivatives CESCO-CANCIAN SERGIO 2010-01-07 US disclosed
US-3954811-A PROSTAGLANDIN INTERMEDIATES SUMITOMO CHEMICAL CO., LTD. (JA) 1976-05-04 US disclosed